Conditions: Dyslipidemia
Keywords: High cholesterol Treatment for high cholesterol Lowering cholesterol Lowering high cholesterol Hypercholesterolemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 27564
Healthy volunteers: no

Brief summary:
The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.

Detailed description:

Arms:
arm 1: Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. arm 2: Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.

Interventions: intervention 1: Evolocumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen. intervention 2: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Protocol document: